As of 27 Jan 2021, more than 113,000 people has received their vaccination and 50 individuals have also received the second dose.
Earlier today, HSA has reviewed another vaccine known as the Moderna Covid-19 vaccine, the agency said: “HSA’s review of the available clinical data found that the benefits of the Moderna Covid-19 vaccine outweigh the known risks “
The Moderna COVID-19 vaccine is the second COVID-19 vaccine to be granted interim authorisation under PSAR.
94% efficacy against COVID-19
“HSA’s review of the available clinical data found that the vaccine demonstrated a high vaccine efficacy of 94%. This means that there is a 94% reduction of symptomatic COVID-19 disease in a vaccinated group of people as compared to a similarly sized group of unvaccinated people. This vaccine efficacy was based on a Phase III clinical trial conducted in over 30,000 clinical trial participants whose ages ranged from 18 to 95 years“, said the agency
The Ministry of Health (MOH) and Health Sciences Authority (HSA) are closely monitoring the safety profile and will continue to do so.
Sight effects
- severe allergic reactions for some people
- pain
- swelling at the injection site
- fatigue, headache
- muscle ache
- fever
- chills
- vomiting
- joint pain